Dr. David Rimm Joins Biocept, Inc. as a Scientific Advisor

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Dr. David Rimm Joins Biocept, Inc. as a Scientific Advisor

SAN DIEGO, March 2, 2015 (GLOBE NEWSWIRE) -- Biocept , Inc. (Nasdaq: BIOC ), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA and circulating tumor cells (CTCs), today announced that David Rimm, M.D., Ph.D., Professor of Pathology and Professor of Medicine in Medical Oncology at Yale University School of Medicine, will join the Company as a scientific advisor. 

Dr. Rimm is a noted physician and researcher in the area of clinically-actionable oncology biomarkers. In his advisory role at Biocept, Dr. Rimm plans to focus on the development of CTC-based biomarker tests targeted on Programmed Death Ligand or PD-L1, an important marker in the emerging area of immuno-oncology therapies.

Some researchers believe that upregulation of PD-L1 allows cancers to evade the host immune system. This research has encouraged development of PD-L1 inhibitor cancer therapies, some that are currently FDA-approved, and many others that are in clinical trials.

"We are very excited to have a physician and personalized medicine expert as accomplished as Dr. Rimm collaborate with our team to help drive our company's scientific strategy," said Michael Nall, President and CEO of Biocept. "We believe Dr. Rimm's experience in translational medicine and cancer biomarkers will help advance Biocept's goal of increasing test offerings tailored to existing and emerging cancer therapies based on a patient's genetic signature, with the goal of improving treatment outcomes."

Dr. Rimm also plans to contribute his expertise to help Biocept expand its menu of blood-based biomarkers.

"The ability to qualify patients for targeted therapy in the absence of biopsy tissue, through a simple blood test, is a provocative concept," Dr. Rimm said. "This is especially true for PD-L1 axis immuno-oncology therapeutics where tumors are very heterogeneous in their expression of PD-L1, meaning, multiple tissue biopsies of the same tumor may not return the same pathological result. The ability to track and monitor patients around this biomarker could be critical for future patient management."

About Biocept, Inc.

Biocept, Inc., headquartered in San Diego, Calif., is a commercial-stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its proprietary technology platform to help improve individual patient treatment. Biocept has developed proprietary technology platforms for capture and analysis of circulating tumor DNA, both in circulating tumor cells (CTCs) and in plasma (cell free tumor DNA). A standard blood sample is utilized to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-GA TM , OncoCEE-BR TM and OncoCEE-LUNG TM test, respectively for gastric, breast and lung cancer and plans to introduce additional CLIA validated tests for lung, colorectal, prostate and other solid tumors based on its proprietary technology platforms over the coming months.

About David Rimm, M.D., Ph.D.

Dr. David Rimm is a Professor in the Department of Pathology at the Yale University School of Medicine. He completed an MD-PhD at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. He is board certified in Anatomic Pathology and Cytopathology. Dr. Rimm is the Director of Yale Pathology Tissue Services and acting director of Molecular Diagnostics. His laboratory group focuses on quantitative pathology related to predicting response to therapy and predicting recurrence or metastasis in breast and lung cancer. He is the author of over 300 peer-reviewed journal papers and eight patents and was co-founder of HistoRx, (a digital pathology company sold to Genoptix in 2012) and Metamark Genetics, a prognostic determinant company.

Forward-Looking Statements Disclaimer Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to Dr. Rimm's ability to contribute to the advancement of our tests and other product offerings and our impact on diagnostic strategies, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the Securities and Exchange Commission, which can be accessed over the Internet at the SEC's website located at www.sec.gov .

Investor Contact: The Ruth Group David Burke Tel: 646-536-7009

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Central Florida Buyers Face the Cash Reality First

Updated Category News Views 94

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 79

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 24

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 53

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 103

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Minnesota Giving Record Signals a Stressed Safety Net

Updated Category News Views 63

Thirty-eight million dollars landing in one day is no small civic heartbeat. Minnesota’s Give to the Max Day brought in a record $38.4 million in 2026 for nearly 6,000 nonprofits and schools, edging past the $37.8 million raised in 2025. More than 65,000 people gave. That deserves a clear-eyed nod, not a cynical shrug. Still, the number carries two messages at once. It...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 36

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 18

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading

Top 5 Most Recently Viewed Articles

BlackBerry QNX and Pi Square Join Forces to Advance Indian Tech

Updated Category News Views 333

BlackBerry QNX Partners with Pi Square Technologies BlackBerry Limited (NYSE: BB) is experiencing a notable increase in share prices, reflecting growing investor confidence. Expanding Horizons for Engineers Recently, BlackBerry’s QNX division announced an exciting multi-year collaboration with Pi Square Technologies. This initiative aims to train thousands of engineers...

Continue Reading
Investors Urged to Act: Investigating DexCom Securities Claims

Updated Category News Views 67

Understanding the Ongoing Investigations into DexCom Faruqi & Faruqi, LLP, a prominent national securities law firm, is currently investigating potential claims on behalf of investors affected by losses in DexCom, Inc. (NASDAQ: DXCM). This inquiry is a direct response to significant concerns raised about the company's business practices and market performance. The Scope...

Continue Reading
Legal Battle Heats Up for Michigan Auto Attorney Over CURE

Updated Category News Views 299

Michigan Attorney Faces Legal Challenges Amid CURE Controversy In a recent turn of events, an attorney from Michigan is experiencing the challenges of navigating legal waters after speaking out against CURE Auto Insurance. The attorney, Steven M. Gursten, along with his firm Michigan Auto Law, is embroiled in lawsuits that highlight serious concerns about consumer...

Continue Reading
Investors of Joint Stock Company Kaspi.kz (KSPI) Take Action Now

Updated Category News Views 120

Investors of Joint Stock Company Kaspi.kz (NASDAQ: KSPI) Take Action Attention investors of Joint Stock Company Kaspi.kz, also known as KSPI! A recent report has raised serious concerns regarding the company's activities, prompting investors who have experienced losses to consider their options in filing a securities fraud lawsuit. These troubling developments are crucial...

Continue Reading
Investors Guide: Urgent Action Needed for Western Asset Fund

Updated Category News Views 130

Introduction to the Class Action The Rosen Law Firm, a prominent name in investor rights advocacy, is urging investors in the Western Asset Management Company mutual funds to take action before an important deadline. If you invested in the 'Western Asset US Core Bond Fund' or the 'Western Asset Core Plus Bond Fund' during the designated class period, this message is...

Continue Reading